From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Dr. Martens – Q3 ‘in line with full year guidance’, but that’s not really an achievement!…

By Steve Moore | Thursday 25 January 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Footwear brand company Dr. Martens (DOCS) has issued its third quarter, to end-December, trading statement with CEO Kenny Wilson commencing that, “Our Q3 performance is in line with the updated full year guidance provided in November” and concluding “we are taking action to continue to grow our iconic brand and invest in our business. We remain confident in our product pipeline for AW24 and beyond”. What of a current around 81p share price in response to the announcement?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Black-Swan

Video: Poking Bears And Black Swans

 

SBTX

Is Stuart Ashman lying again?

 

Crime-Scene

So farewell then MichaelWalters.com

Time left: 18:55:23